Parexel’s Stacy Hurt draws on her experience with chemotherapy and as a caregiver to spot patient burdens that AI-assisted ...

Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the ...

However, despite this progress, the bioprocessing industry still struggles to use this data in a way that consistently ...

Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...

The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors ...

There’s little doubt that Daiichi Sankyo has carved out a stronghold in the market for antibody-drug conjugates. Buoyed by its roster of ADCs, the company’s first-quarter revenue rose 21% over the ...

Pharma has more drugs to test. But the system built to test them is under strain. The number of drugs in phase 2 and 3 has climbed about 9% year over year, according to a new analysis by Bain & ...

Roche and Genentech’s multiple sclerosis drug Ocrevus launched like a firework in 2017, achieving blockbuster status within a year while making a mark on an already crowded market with a brand-new ...

Last year, Bristol Myers Squibb put a spotlight on the kind of cash that comes with pharma’s conviction in a new oncology strategy. The drugmaker agreed to pay BioNTech $1.5 billion upfront and ...

What if a cancer drug works, but not the way scientists thought it would? A recent study found evidence of just that in laboratory models of glioblastoma, involving the research compound QC6352 and a ...